CX501
DrugCultured chimeric skin
NCT Number: NCT00987142
A phase II, comparative, open label, prospective, multicentre clinical trial where each patient will undergo two procedures; implant of a patch of cultured chimeric skin (experimental therapy) in a half of the skin lesion and an occlusive non-adherent dressing (control) in the other half for 12 months of follow-up in two Spanish centres.
Looking for future studies?
Notify Me28 day and older
All sexes
Interventional
Phase 2
Fundación Mir-Mir, Barcelona, Spain
Reconstruction of interdigital commisures in patients with severe skin syndactyly using laminar grafts that will be uniformly and systematically taken with an electrical or compressed air dermatome on an aseptic area and with the same extent and depth in microns in all patients.
Immediately after the surgical procedure, a patch of cultured chimeric skin (experimental therapy) will be implanted in a half of the skin defect of the patient, and an occlusive non - adherent dressing (control) will be implanted in the other half.
Patients will initially be followed up every two days until epithelisation occurs (approximately 21 days after surgery) and at 3,8,and 12 months of follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cultured chimeric skin
Application of an occlusive non adherent dressing in the skin donor site
Time frame: 21 days
Time frame: 3, 8 and 12 months
Time frame: 12 months
Tigenix S.A.U.
Industry
A Comparative Open-Label Multicentre Clinical Trial To Assess The Efficacy And Safety Of A New Therapy With Cultured Chimeric Skin For The Treatment Of Skin Lesions In Patients With Epidermolysis Bullosa
Acronym: TCEB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04853667
Agnosia, Congenital Abnormalities
Paris, France
View Trial DetailsNCT03730584
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Paris, France
View Trial DetailsNCT05533866
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Chicago, Illinois, United States
View Trial DetailsNCT03928093
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Toronto, Ontario, Canada
View Trial Details